Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department

Migraine Without Aura Clinical Trial

— EDMigraine-4  

Official title:

Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01596166
• Other study ID #: EDMIGR-004-01
• Status: Completed
• Phase: Phase 4
• First received: May 8, 2012
• Last updated: January 21, 2015
• Start date: February 2012
• Est. completion date: April 2014

Study information

• Verified date: January 2015
• Source: University of Alberta
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Migraine headaches are a common problem for children. When treatment at home fails, children may benefit from intravenous treatment administered in a hospital setting like the Emergency Department. Most treatments used however have only been tested in adults and the best treatment strategy for children is not always clear. The combination of more than one medication is frequently prescribed in Canadian Emergency Departments. The purpose of this study is to investigate whether the combination of ketorolac (an anti-inflammatory pain medication) and metoclopramide (an anti-nauseant that may also relieve migraine headaches) is better than metoclopramide by itself.

Description:

Migraine headache is a painful condition of recurrent moderate to severe head pain associated with nausea, vomiting, photophobia, and phonophobia. The condition is highly prevalent and a significant community health problem with considerable impact on the health care system. To alleviate the pain and morbidity associated with a migraine attack, drug therapies are often employed including simple analgesics like ibuprofen and migraine-specific medications like sumatriptan. When these treatments fail or in severe, intractable cases, patients and families may present to the Emergency Department (ED).

Ketorolac in combination with metoclopramide or prochlorperazine was the most common multi-drug combination used in 36% of ED presentations for migraine across Canada in our national practice variation study. The scientific rationale for combining a non-selective non-steroidal anti-inflammatory drug (NSAID) with inhibition of both the cyclooxygenase (COX) 1 and 2 isoenzymes with other migraine therapies is enticing; however, no studies have specifically examined the relative efficacy of the practice. Why would the combination of a non-selective NSAID like ketorolac with other migraine therapies improve treatment outcomes? The benefit of multi-target combinations may be relate to the duration of the migraine and the multiple brain areas involved in sustained pain. It has long been recognized that patients who treat their migraine headaches early at the onset have a better response. The underlying mechanism for this phenomenon has now been identified. The initiation of migraine pain requires activation of the trigeminal (5th cranial nerve) nociceptive (pain) system. Activation of these sensory fibers within the arachnoid membrane on the surface of the brain produces the first and most common painful manifestation of migraine - the pulsatile headache. With each heartbeat, minor dilation of the cerebral blood vessels produces stretch and a painful activation of the trigeminal fibers known as peripheral sensitization. The second phase in the maintenance of a migraine attack over several hours is the sensitization of trigeminal pain pathways leading to higher brain centers known as central sensitization. The efficacy of medications like the triptans is greater early in the course of a migraine attack when there is only peripheral sensitization and before the onset of central sensitization. Non-selective NSAIDs like naproxen sodium and ketorolac may be uniquely effective in the reduction of central sensitization in the animal model of migraine and the reduction of migraine pain in adult patients late in the course of a migraine headache.

The population of patients in the ED is uniquely different from outpatients in that most have developed their migraine headache hours or days before presenting. In our practice variation study, the mean duration of the migraine prior to presenting to the ED was 2 days. Including an NSAID when treating a prolonged migraine in the ED may thus increase the therapeutic window and improve outcomes. While many Canadian ED physicians have adopted the practice of combining ketorolac with other migraine therapies, the gold standard assessment of efficacy and safety in a randomized clinical trial has not been applied.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Years to 17 Years

Eligibility

Inclusion Criteria:

A patient is legible to participate in this study if they meet the following criteria:

1. Patient is between 6 and 17 years of age inclusive

2. Treatment with usual therapy at home or at least one dose of oral ibuprofen or acetaminophen has not provided satisfactory relief

3. Intravenous therapy is indicated in the opinion of the treating ED physician

4. Patient has a history of migraine as defined by the International Classification of Headache Disorders - 2nd edition (Appendix 1) and meets the following criteria:

1. During headache, at least 1 of the following: nausea and/or vomiting; two of five symptoms (photophobia, phonophobia, difficulty thinking, lightheadedness, or fatigue). Symptoms may be inferred from patient's behavior.

2. Headache has at least 2 of the following characteristics: bifrontal/bitemporal or unilateral location; pulsating/throbbing quality; moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity. Symptoms may be inferred from patient's behavior.

Exclusion Criteria:

A patient is not eligible to participate in the study if any of the following criteria apply:

1. Patient has a contraindication to the use of metoclopramide or ketorolac in the opinion of the ED physician

2. Patient has a ventriculoperitoneal shunt

3. Patient has a fever (temperature > 38.5 oC)

4. Patient has meningismus or clinical suspicion of meningitis in the opinion of the ED physician

5. Patient has a history of head trauma causing headache in the last 1 week prior to presentation to the ED

6. Patient is unable to complete the efficacy assessments (e.g. language barrier)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Emergencies
• Migraine Disorders
• Migraine with Aura
• Migraine Without Aura
• Probable Migraine

Intervention

Drug:
• Ketorolac Tromethamine
Ketorolac 0.5 mg/kg (max 30 mg) IV
• Metoclopramide
Metoclopramide 0.2 mg/kg (max 10 mg) IV

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta
Canada	Stollery Children's Hospital	Edmonton	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Alberta	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean reduction in pain intensity	Measured on Visual Analogue Scale (VAS).	2 hours	No
Secondary	Pain freedom	VAS=0	2 hours	No
Secondary	Headache relief - 33	Defined as a 33% reduction on the VAS.	2 hours	No
Secondary	Headache relief - 50	Defined as a 50% reduction on the VAS	2 hours	No
Secondary	Presence of nausea		2 hours	No
Secondary	Presence of vomiting		2 hours	No
Secondary	Use of rescue medications	Permitted per protocol 60 minutes after start if intravenous infusion.	2 hours	No
Secondary	Sustained pain-free	No recurrence of headache within 24 hours if pain was completely eliminated (VAS = 0) prior to discharge.	25 hours	No
Secondary	Sustained headache relief	No increase in headache by 33% on the VAS or 50% on the VAS if headache relief was initially achieved.	24 hours	No
Secondary	Minimum clinically significant difference	"I would take the medication again"; "My headache is a bit better/worse"; "My headache is a lot better/worse"	2 hours	No
Secondary	Adverse events	All serious and non-serious adverse events including akathisia and dystonia.	2 hours	Yes